Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Education Library
  3. ESMO Webinars
  4. ESMO Virtual Journal Club - Webinar Series

ESMO Virtual Journal Club: May 2024

Aired live on 22 May 2024

ESMO-Webinar-Series-Virtual-Journal-Club-General-1000x1000

This content is for ESMO members only.

Login

Learn more about how you can join ESMO

Presentation

78 slides, 65 min

Download slides

Programme

  • 22 May 2024
Welcome and introduction
Evandro de Azambuja
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Benjamin Besse
Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
Patrizia Giannatempo
Ribociclib plus endocrine therapy in early breast cancer
Valentina Guarneri
Live Q&A and Discussion
All speakers

Speakers

Description and DOIs

The first ESMO Virtual Journal Club Webinar focused on three newly published studies, with an aim to enhance understanding and application of the latest research in the field.

This webinar aimed to discuss and evaluate notable recent publications on the topics of non-small cell lung cancer, urothelial cancer, and breast cancer:

  • Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77-90. doi:10.1016/j.annonc.2023.10.117
  • Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875-888. doi:10.1056/NEJMoa2312117
  • Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024;390(12):1080-1091. doi:10.1056/NEJMoa2305488

Learning objectives

  • To discuss and critically evaluate notable recent publications.
  • To enhance the understanding and application of the latest research in the field.
  • To assess the study’s robustness, its significance to oncology practice, limitations, and its place within existing research.
  • To identify and highlight any unclear aspects or unmet needs.

Speakers

You may also be interested in...

ESMO Virtual Journal Club

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.